{"id":"NCT03429049","sponsor":"Centrexion Therapeutics","briefTitle":"A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection of CNTX-4975-05 in Subjects With Chronic, Moderate-to-severe Osteoarthritis Knee Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-24","primaryCompletion":"2019-11-22","completion":"2019-11-22","firstPosted":"2018-02-12","resultsPosted":"2022-04-08","lastUpdate":"2022-07-26"},"enrollment":332,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee"],"interventions":[{"type":"DRUG","name":"CNTX-4975-05","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"CNTX-4975-05","type":"EXPERIMENTAL"}],"summary":"This is a phase 3, randomized, double-blind, placebo-controlled, single injection, 52-week study to evaluate the analgesic efficacy and safety of a single intra-articular (IA) CNTX-4975-05 (capsaicin), compared to IA placebo, in subjects with chronic, moderate-to-severe osteoarthritis (OA) knee pain.","primaryOutcome":{"measure":"Change From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-2.84,"sd":0.212},{"arm":"CNTX-4975-05","deltaMin":-3.17,"sd":0.182}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1904"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":15},"locations":{"siteCount":33,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":136},"commonTop":["Arthralgia","Upper respiratory tract infection","Nausea","Osteoarthritis","Dizziness"]}}